Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:4 Number:79 ISSN#:2563-5476
RCT
ACE Report #6203
Ace Report Cover Metabolic Disorders

WCO-IOF: Changes with QCT, DXA, and TBS between denosumab, alendronate, & placebo


Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Changes in lumbar spine QCT, DXA, and TBS following treatment with denosumab (DMAB), alendronate (ALN), or placebo (PBO) in postmenopausal women with low bone mass

Contributing Authors: T Thomas AM Cheung E Shane JR Zanchetta A Kearns D Hans CJF Lin M Austin C Libanati

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Synopsis

215 postmenopausal women with low spine or total hip bone mineral density (BMD) were randomized to treatment with either denosumab, alendronate, or placebo for a period of 12 months. Quantitative computed tomography (QCT) and densitometry (DXA), in addition to a novel trabecular bone score (TBS) were evaluated to determine if a differences exists between the information provided by these three mea...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.